NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Dr. David Greenberg outlines bladder cancer staging, BCG, immunotherapy, surgery, quality of life impacts and long-term ...

Mitomycin gel has a favorable durability of response rate at 24 months among treated trial patients with low grade, intermediate-risk non-muscle invasive bladder cancer.

Non–muscle-invasive bladder cancer (NMIBC), seen in about 75% of newly diagnosed patients, is confined to the urothelial lining of the bladder and poses no immediate threat to life. However, almost 40 ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Session Date and Time: Friday, May 15, 2026, at 3:30 p.m. – 5:30 p.m.

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...